AI assistant
Dare Bioscience, Inc. — Director's Dealing 2016
Jan 19, 2016
34825_dirs_2016-01-19_606bb8e6-2ae9-4795-9432-b19e88532b1d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cerulean Pharma Inc. (CERU)
CIK: 0001401914
Period of Report: 2016-01-14
Reporting Person: WALT DAVID R (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-01-14 | Common Stock | P | 4400 | $2.6427 | Acquired | 67031 | Direct |
| 2016-01-15 | Common Stock | P | 4172 | $2.4169 | Acquired | 71203 | Direct |
Footnotes
F1: These purchases were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2015.
F2: Represents the weighted average purchase price for shares purchased in multiple transactions. Purchase prices ranged from $2.60 to $2.70 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.
F3: Represents the weighted average purchase price for shares purchased in multiple transactions. Purchase prices ranged from $2.33 to $2.51 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.